- Home
- OMCL
as 03-28-2025 4:00pm EST
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | FORT WORTH |
| Market Cap: | 1.5B | IPO Year: | 2001 |
| Target Price: | $51.00 | AVG Volume (30 days): | 670.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.12 - $55.75 | Next Earning Date: | 05-01-2025 |
| Revenue: | $1,112,238,000 | Revenue Growth: | -3.04% |
| Revenue Growth (this year): | 4.02% | Revenue Growth (next year): | 4.32% |
Latest Omnicell Inc. ($0.001 par value) News
OMCL Breaking Stock News: Dive into OMCL Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
OMCL: Raising target price to $36.00
Zacks
4 days ago
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
MT Newswires
5 days ago
Omnicell Names Chief Technology Officer
Business Wire
5 days ago
Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer
Argus Research
9 days ago
Daily – Vickers Top Buyers & Sellers for 03/20/2025
Argus Research
10 days ago
Daily – Vickers Top Buyers & Sellers for 03/19/2025
MT Newswires
11 days ago
Omnicell Insider Bought Shares Worth $349,874, According to a Recent SEC Filing
Simply Wall St.
17 days ago
Omnicell's (NASDAQ:OMCL) Earnings Seem To Be Promising
Compare OMCL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMCL Omnicell Inc. ($0.001 par value) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.